In the last 12 months, insiders at Contineum Therapeutics, Inc. ($CTNM) filed 98 transactions with the SEC: 0 open-market purchases totaling $0 and 20 sales totaling $744,299. Net insider sentiment: net selling.
Contineum Therapeutics, Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Lorrain Daniel S. (Chief Scientific Officer) — 27 transactions totaling $483,915
- Watkins Tim (CMO & Head of Development) — 13 transactions totaling $197,715
- Stengone Carmine N. (CEO and President) — 12 transactions totaling $129,578
- Huhn Stephen L. (CMO & Sr VP, Clinical Dev.) — 4 transactions totaling $12,928
- Healy John Stephen (General Counsel and Corp Sec) — 3 transactions totaling $0
View all SEC Filings for Contineum Therapeutics, Inc. (CTNM).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Watkins Tim | CMO & Head of Development | M | Stock Option (right to buy) | 3611 | $0.00 | 249,167.0000 | 28,115,548 | 1.43% | 0.01% |
| March 2, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 4170 | $15.01 | 158,724.0000 | 28,115,548 | 2.56% | 0.01% |
| March 2, 2026 | Watkins Tim | CMO & Head of Development | M | Class A Common Stock | 3611 | $4.50 | 3,611.0000 | 28,115,548 | 9999.99% | 0.01% |
| March 2, 2026 | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 3611 | $15.02 | 0.0000 | 28,115,548 | 100.00% | 0.01% |
| Feb. 25, 2026 | Stengone Carmine N. | CEO and President | M | Stock Option (right to buy) | 2700 | $0.00 | 120,917.0000 | 28,115,548 | 2.18% | 0.01% |
| Feb. 24, 2026 | Stengone Carmine N. | CEO and President | M | Class A Common Stock | 4400 | $1.26 | 19,354.0000 | 28,115,548 | 29.42% | 0.02% |
| Feb. 24, 2026 | Stengone Carmine N. | CEO and President | S | Class A Common Stock | 4400 | $16.02 | 14,954.0000 | 28,115,548 | 22.73% | 0.02% |
| Feb. 25, 2026 | Stengone Carmine N. | CEO and President | M | Class A Common Stock | 2700 | $1.26 | 17,654.0000 | 28,115,548 | 18.06% | 0.01% |
| Feb. 25, 2026 | Stengone Carmine N. | CEO and President | S | Class A Common Stock | 2700 | $16.02 | 14,954.0000 | 28,115,548 | 15.29% | 0.01% |
| Feb. 25, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 3824 | $0.00 | 67,306.0000 | 28,115,548 | 5.38% | 0.01% |
| Feb. 24, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 4300 | $0.00 | 71,130.0000 | 28,115,548 | 5.70% | 0.02% |
| Feb. 25, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 3824 | $16.01 | 162,894.0000 | 28,115,548 | 2.29% | 0.01% |
| Feb. 25, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 3824 | $1.01 | 166,718.0000 | 28,115,548 | 2.35% | 0.01% |
| Feb. 24, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 4300 | $16.03 | 162,894.0000 | 28,115,548 | 2.57% | 0.02% |
| Feb. 24, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 4300 | $1.01 | 167,194.0000 | 28,115,548 | 2.64% | 0.02% |
| Feb. 24, 2026 | Stengone Carmine N. | CEO and President | M | Stock Option (right to buy) | 4400 | $0.00 | 123,617.0000 | 28,115,548 | 3.44% | 0.02% |
| Feb. 19, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 100 | $0.00 | 75,430.0000 | 28,115,548 | 0.13% | 0.00% |
| Feb. 19, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 100 | $1.01 | 162,994.0000 | 28,115,548 | 0.06% | 0.00% |
| Feb. 19, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 100 | $16.00 | 162,894.0000 | 28,115,548 | 0.06% | 0.00% |
| Feb. 11, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Stock Option (right to buy) | 400 | $0.00 | 75,530.0000 | 28,115,548 | 0.53% | 0.00% |
| Feb. 11, 2026 | Stengone Carmine N. | CEO and President | S | Class A Common Stock | 400 | $16.00 | 14,954.0000 | 28,115,548 | 2.61% | 0.00% |
| Feb. 11, 2026 | Stengone Carmine N. | CEO and President | M | Class A Common Stock | 400 | $1.26 | 15,354.0000 | 28,115,548 | 2.67% | 0.00% |
| Feb. 11, 2026 | Stengone Carmine N. | CEO and President | M | Stock Option (right to buy) | 400 | $0.00 | 128,017.0000 | 28,115,548 | 0.31% | 0.00% |
| Feb. 11, 2026 | Lorrain Daniel S. | Chief Scientific Officer | M | Class A Common Stock | 400 | $1.01 | 163,294.0000 | 28,115,548 | 0.25% | 0.00% |
| Feb. 11, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 400 | $16.00 | 162,894.0000 | 28,115,548 | 0.24% | 0.00% |
| Feb. 3, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 1170 | $15.25 | 162,894.0000 | 28,115,548 | 0.71% | 0.00% |
| Feb. 3, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 3000 | $14.82 | 164,064.0000 | 28,115,548 | 1.80% | 0.01% |
| Jan. 30, 2026 | Healy John Stephen | General Counsel and Corp Sec | A | Stock Option (right to buy) | 206411 | $0.00 | 206,411.0000 | 28,115,548 | 9999.99% | 0.73% |
| Jan. 30, 2026 | Watkins Tim | CMO & Head of Development | A | Stock Option (right to buy) | 160000 | $0.00 | 160,000.0000 | 28,115,548 | 9999.99% | 0.57% |
| Jan. 28, 2026 | Watkins Tim | CMO & Head of Development | M | Stock Option (right to buy) | 3611 | $0.00 | 252,778.0000 | 28,115,548 | 1.41% | 0.01% |
| Jan. 28, 2026 | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 811 | $14.48 | 0.0000 | 28,115,548 | 100.00% | 0.00% |
| Jan. 28, 2026 | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 2800 | $14.09 | 811.0000 | 28,115,548 | 77.54% | 0.01% |
| Jan. 28, 2026 | Watkins Tim | CMO & Head of Development | M | Class A Common Stock | 3611 | $4.50 | 3,611.0000 | 28,115,548 | 9999.99% | 0.01% |
| Jan. 30, 2026 | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 6500 | $0.00 | 166,500.0000 | 28,115,548 | 4.06% | 0.02% |
| Jan. 30, 2026 | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 160000 | $0.00 | 166,500.0000 | 28,115,548 | 2461.54% | 0.57% |
| Jan. 30, 2026 | Stengone Carmine N. | CEO and President | A | Stock Option (right to buy) | 445000 | $0.00 | 445,000.0000 | 28,115,548 | 9999.99% | 1.58% |
| Jan. 30, 2026 | Slover Peter T | Chief Financial Officer | A | Stock Option (right to buy) | 192000 | $0.00 | 192,000.0000 | 28,115,548 | 9999.99% | 0.68% |
| Jan. 5, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 3670 | $10.35 | 167,564.0000 | 28,115,548 | 2.14% | 0.01% |
| Jan. 5, 2026 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 500 | $11.13 | 167,064.0000 | 28,115,548 | 0.30% | 0.00% |
| Dec. 23, 2025 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 4170 | $12.23 | 171,234.0000 | 28,115,548 | 2.38% | 0.01% |
| Dec. 29, 2025 | Watkins Tim | CMO & Head of Development | M | Stock Option (right to buy) | 3611 | $0.00 | 256,389.0000 | 28,115,548 | 1.39% | 0.01% |
| Dec. 29, 2025 | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 3611 | $12.06 | 0.0000 | 28,115,548 | 100.00% | 0.01% |
| Dec. 29, 2025 | Watkins Tim | CMO & Head of Development | M | Class A Common Stock | 3611 | $4.50 | 3,611.0000 | 28,115,548 | 9999.99% | 0.01% |
| June 26, 2025 | Schimmelpennink Evert B. | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| June 26, 2025 | Miralles Gines Diego | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| June 26, 2025 | Ware Olivia C | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| June 26, 2025 | Lyons-Williams Lori | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| June 26, 2025 | Ignelzi Troy A. | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| June 26, 2025 | Boyce Sarah | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| June 26, 2025 | Brady Todd R. | Director | A | Stock Option (right to buy) | 14750 | $0.00 | 14,750.0000 | 19,352,859 | 9999.99% | 0.08% |
| April 28, 2025 | Watkins Tim | CMO & Head of Development | A | Stock Option (right to buy) | 26000 | $0.00 | 26,000.0000 | 19,352,859 | 9999.99% | 0.13% |
| April 28, 2025 | Watkins Tim | CMO & Head of Development | A | Stock Option (right to buy) | 260000 | $0.00 | 260,000.0000 | 19,352,859 | 9999.99% | 1.34% |
| March 14, 2025 | Miralles Gines Diego | Director | A | Stock Option (right to buy) | 29500 | $0.00 | 29,500.0000 | 19,352,859 | 9999.99% | 0.15% |
| Jan. 31, 2025 | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 110000 | $0.00 | 113,700.0000 | 19,352,859 | 2972.97% | 0.57% |
| Jan. 31, 2025 | Healy John Stephen | General Counsel and Corp Sec | A | Stock Option (right to buy) | 63589 | $0.00 | 63,589.0000 | 19,352,859 | 9999.99% | 0.33% |
| Jan. 31, 2025 | Slover Peter T | Chief Financial Officer | A | Stock Option (right to buy) | 110000 | $0.00 | 110,000.0000 | 19,352,859 | 9999.99% | 0.57% |
| Jan. 31, 2025 | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 3700 | $0.00 | 113,700.0000 | 19,352,859 | 3.36% | 0.02% |
| Jan. 31, 2025 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | A | Stock Option (right to buy) | 110000 | $0.00 | 110,000.0000 | 19,352,859 | 9999.99% | 0.57% |
| Jan. 31, 2025 | Stengone Carmine N. | CEO and President | A | Stock Option (right to buy) | 300000 | $0.00 | 300,000.0000 | 19,352,859 | 9999.99% | 1.55% |
| Nov. 25, 2024 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 1010 | $16.02 | 172,460.0000 | 25,730,014 | 0.58% | 0.00% |
| Nov. 18, 2024 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 6091 | $16.37 | 173,569.0000 | 25,730,014 | 3.39% | 0.02% |
| Nov. 18, 2024 | Lorrain Daniel S. | Chief Scientific Officer | S | Class A Common Stock | 99 | $17.05 | 173,470.0000 | 25,730,014 | 0.06% | 0.00% |
| Aug. 13, 2024 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | M | Stock Option (right to buy) | 12800 | $0.00 | 161,394.0000 | 2,308,972 | 7.35% | 0.55% |
| Aug. 13, 2024 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | M | Class A Common Stock | 12800 | $1.01 | 12,800.0000 | 2,308,972 | 9999.99% | 0.55% |
| June 24, 2024 | Boyce Sarah | Director | A | Stock Option (right to buy) | 29500 | $0.00 | 29,500.0000 | 2,308,972 | 9999.99% | 1.28% |
| June 3, 2024 | Healy John Stephen | General Counsel and Corp Sec | A | Stock Option (right to buy) | 160000 | $0.00 | 160,000.0000 | 2,308,972 | 9999.99% | 6.93% |
| May 24, 2024 | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 3700 | $0.00 | 103,700.0000 | 2,308,972 | 3.70% | 0.16% |
| May 24, 2024 | Lorrain Daniel S. | Chief Scientific Officer | A | Stock Option (right to buy) | 100000 | $0.00 | 103,700.0000 | 2,308,972 | 2702.70% | 4.33% |
| May 24, 2024 | Stengone Carmine N. | CEO and President | A | Stock Option (right to buy) | 285000 | $0.00 | 285,000.0000 | 2,308,972 | 9999.99% | 12.34% |
| May 24, 2024 | Slover Peter T | Chief Financial Officer | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 2,308,972 | 9999.99% | 4.33% |
| May 24, 2024 | Schimmelpennink Evert B. | Director | A | Stock Option (right to buy) | 29500 | $0.00 | 29,500.0000 | 2,308,972 | 9999.99% | 1.28% |
| May 24, 2024 | Brady Todd R. | Director | A | Stock Option (right to buy) | 29500 | $0.00 | 29,500.0000 | 2,308,972 | 9999.99% | 1.28% |
| May 24, 2024 | Lyons-Williams Lori | Director | A | Stock Option (right to buy) | 29500 | $0.00 | 29,500.0000 | 2,308,972 | 9999.99% | 1.28% |
| May 24, 2024 | Ware Olivia C | Director | A | Stock Option (right to buy) | 3700 | $0.00 | 3,700.0000 | 2,308,972 | 9999.99% | 0.16% |
| May 24, 2024 | Ignelzi Troy A. | Director | A | Stock Option (right to buy) | 6350 | $0.00 | 6,350.0000 | 2,308,972 | 9999.99% | 0.28% |
| May 24, 2024 | Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 2,308,972 | 9999.99% | 4.33% |
| May 20, 2024 | Ignelzi Troy A. | Director | A | Stock Option (right to buy) | 23150 | $0.00 | 23,150.0000 | 2,308,972 | 9999.99% | 1.00% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Class A Common Stock | 148312 | $0.00 | 523,847.0000 | 2,308,972 | 39.49% | 6.42% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series C Preferred Stock | 275769 | $0.00 | 710,494.0000 | 2,308,972 | 63.44% | 11.94% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Class A Common Stock | 391785 | $0.00 | 767,320.0000 | 2,308,972 | 104.33% | 16.97% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Class A Common Stock | 2531 | $0.00 | 378,066.0000 | 2,308,972 | 0.67% | 0.11% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series C Preferred Stock | 689 | $0.00 | 12,123.0000 | 2,308,972 | 6.03% | 0.03% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series C Preferred Stock | 110187 | $0.00 | 1,934,776.0000 | 2,308,972 | 6.04% | 4.77% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series B Preferred Stock | 317988 | $0.00 | 2,175,832.0000 | 2,308,972 | 17.12% | 13.77% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series B Preferred Stock | 434725 | $0.00 | 2,175,832.0000 | 2,308,972 | 24.97% | 18.83% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series B Preferred Stock | 2182 | $0.00 | 1,752,541.0000 | 2,308,972 | 0.12% | 0.09% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series B Preferred Stock | 348143 | $0.00 | 3,565,696.0000 | 2,308,972 | 10.82% | 15.08% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series A-1 Preferred Stock | 1423119 | $0.00 | 1,423,119.0000 | 2,308,972 | 9999.99% | 61.63% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series A Preferred Stock | 9252 | $0.00 | 9,252.0000 | 2,308,972 | 9999.99% | 0.40% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series A Preferred Stock | 1476446 | $0.00 | 1,476,446.0000 | 2,308,972 | 9999.99% | 63.94% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series C Preferred Stock | 57565 | $0.00 | 0.0000 | 2,308,972 | 0.00% | 2.49% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series C Preferred Stock | 145 | $0.00 | 0.0000 | 2,308,972 | 0.00% | 0.01% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series C Preferred Stock | 22312 | $0.00 | 0.0000 | 2,308,972 | 0.00% | 0.97% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series B Preferred Stock | 90747 | $0.00 | 1,741,107.0000 | 2,308,972 | 5.50% | 3.93% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series B Preferred Stock | 455 | $0.00 | 1,741,107.0000 | 2,308,972 | 0.03% | 0.02% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series B Preferred Stock | 70498 | $0.00 | 1,741,107.0000 | 2,308,972 | 4.22% | 3.05% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series A Preferred Stock | 1931 | $0.00 | 0.0000 | 2,308,972 | 0.00% | 0.08% |
| April 9, 2024 | Versant Venture Capital VI, L.P. | TenPercentOwner | C | Series A Preferred Stock | 298975 | $0.00 | 0.0000 | 2,308,972 | 0.00% | 12.95% |